Unassociated Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8-K
 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 1, 2010
 

RENHUANG PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in its Charter)
 
 
Nevada
  
0-24512
  
88-1273503
(State or Other Jurisdiction
of Incorporation)
  
(Commission File Number)
  
(IRS Employer
Identification No.)

No. 281, Taiping Road, Taiping District
Harbin, Heilongjiang Province, 150050
(Address of Principal Executive Offices)

Registrant’s telephone number, including area code:  86-451-5762-0378

N/A
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
 
Item 8.01 Other Events.
 
On July 1, 2010, Renhuang Pharmaceuticals, Inc.  (“Renhuang”) issued a press release announcing that Renhuang received approval to list its common stock on the NYSE Amex.

A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
 
Renhuang’s common stock ceased trading on the Pink Sheets and commenced trading on the NYSE Amex on July 2, 2010 under the ticker symbol “CBP”.
 
Item 9.01(d). Financial Statements and Exhibits.
 
     
 Exhibit No.
  
Description
     
99.1
  
Press Release dated July 1, 2010
     


 
 
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
         
   
RENHUANG PHARMACEUTICALS, INC.
     
Date: July 2, 2010
  
By:
  
/s/ Shaoming Li
       
Shaoming Li
       
Chief Executive Officer
       
 
 
 
 
 
 

 
EXHIBIT INDEX
 
Exhibit
    
Number
  
Description
99.1
  
Press Release dated July 1, 2010